The Longevity Biotechnology Association proudly welcomes Amaro Therapeutics, Inc. as the newest Collaborative Partner. We are also pleased to recognize J. Michael French, CEO of Amaro Therapeutics, as a valued member of the LBA community. Learn more: linkedin.com/feed/update/urn…

This year’s 12th annual Aging Research & Drug Discovery Meeting (#ARDD2025) brought together an extraordinary program of global thought-leaders actively advancing the science of aging. Learn more: linkedin.com/feed/update/urn…

Exciting news from the LBA’s newest collaborative partner, Eos SENOLYTIX, whose MitoXcel™ Technology targets the age-related decline in mitochondrial membrane potential. Learn more - linkedin.com/feed/update/urn…

The LBA is proud to welcome its newest member, Kevin Slawin MD, Founder and CEO of Eos SENOLYTIX, Inc. To learn more about Eos SENOLYTIX - eossenolytix.com/

The LBA congratulates Gero on its groundbreaking partnership with Chugai Pharmaceutical, a member of the Roche Group. This agreement marks a major step forward for the field of aging therapeutics. To learn more - linkedin.com/posts/longevity…

Join the American Federation for Aging Research (AFAR) for a free webinar, “mHealth for Healthy Aging,” on Wednesday, June 25, from 12:00–1:00 PM ET (9:00–10:00 AM PT). Register: us02web.zoom.us/webinar/regi…

Launching a new initiative with Norway’s HUNT Biobank to explore how molecular changes over time influence healthy aging, @bioagelabs will analyze decades of data from thousands of participants to uncover factors that protect against chronic disease. ir.bioagelabs.com/news-relea…

The THRIVE Act, co-authored by Dr. Zan Fleming, David Fox, & Thomas Seoh—experts in FDA regulation & biotech—the Act outlines a tiered framework to support healthspan interventions. Offering incentives, such as FDA-led guidance, market exclusivity & more. youtu.be/u8XurK-J848

Congratulations to LongeVC (@hqlongevc), collaborative partner of the LBA, on their portfolio company being selected as a semi-finalist in the @xprize Global Healthspan Challenge and a finalist in the @SOLVEFSHD Challenge - earning 2x $250,000 in recognition and funding!

Six LBA partners will be featured at the A4LI Summit, including Eric Morgen (BioAge), Joe Betts-LaCroix (Retro Biosciences), Aurora Griffin (LongeVC), Chris Bradley (Matter Bio), Michael Ringel (Life Biosciences), & Alexandra Bause (Apollo Health Ventures) a4li.org/dc-summit-2025/

The Academy for Health and Lifespan Research, composed of the world’s leading scientists in aging biology, is committed to advancing the promise of geroscience. The biology of aging is modifiable; it can be altered, slowed, and delayed. To extend healthspan and improve quality of life for future generations, research must be prioritized, and funds must be invested in this critical area. In the U.S., we are witnessing a troubling decline in the recognition of the value of basic science and biomedical research—at a time when its promise has never been better. Now more than ever, policymakers and elected officials should act to reverse this trend and provide the sustained support needed to drive scientific progress. Our advancements have been made possible by decades of government-funded research across all areas of science, including chemistry, biology, physics, computer science, and mathematics. Continued decreases in funding will derail future breakthroughs and threaten the U.S.’s role as a global leader in medical innovation. Enhancing healthspan is not only a scientific imperative—it is an economic one. By reducing the burden of chronic illness, geromedicine, based on geroscience, holds the potential to save billions in healthcare costs while enabling longer, healthier, and more productive lives.

Juvenescence, co-founded by LBA member Jim Mellon, was highlighted by Bloomberg for the new strategic partnership and investment from M42 Health. Learn more - bloomberg.com/news/articles/…

The LBA co-founder, @JamesPeyer, hosted a roundtable discussion featuring Alex Colville, Managing Partner at @age1vc. They explored how AGE1 is revolutionizing healthcare by investing in science-driven technologies aimed at extending healthspan. youtu.be/mx3Gq0xwB1k

Vascarta Inc. has released its latest paper, introducing a new approach to #curcumin delivery. Unlike traditional oral administration, this study explores a topical formulation (VASCEPTOR®) designed for more effective absorption. linkedin.com/feed/update/urn…

Join AFAR for a free webinar on emerging technologies in aging research, featuring experts in #bioprinting and organ #regeneration. Moderated by LBA member @SergeyYoung200. Join AFAR from 12-1pm ET on Thursday, March 20th. Learn more & RSVP here: afar.org/events/webinar-emer…

Cellergy Therapeutics, a partner of the LBA, has launched their new website, highlighting their work in producing functional #mitochondria to #restore energy, #combat degenerative diseases, and #promote longevity. To learn more - cellergy-bio.com

LBA partner, @LyGenesis_Inc, reached a major milestone in their Phase 2a clinical trial using allogeneic cell therapy to regenerate liver tissue! They are now enrolling their second patient cohort and escalating the dose as planned. prnewswire.com/news-releases…

A study by LBA collaborator, @BuckInstitute, found that favoring the maternal X chromosome accelerates brain aging and impairs cognition in female mammals. CRISPR reactivation of silenced genes restored memory, revealing potential therapeutic targets. nature.com/articles/s41586-0…

LBA member @aubreydegrey (LEV Foundation) presented at the 11th @ARDD_Meeting. His talk, "Taking Rejuvenation to Longevity Escape Velocity: Combinatorial Rejuvenation in Mice," explored advancements in achieving longevity through rejuvenation strategies. youtube.com/watch?v=EEjsNRYq…

The LBA welcomes Cellergy Therapeutics and its CEO Rachel Diamant. Cellergy Therapeutics aims to revolutionize human health by harnessing the regenerative power of young mitochondria to energize cells, combat degenerative diseases, and promote longevity. cellergy-bio.com